Detection of pancreatic carcinomas by imaging lactose-binding protein expression in peritumoral pancreas using [18F] fluoroethyl-deoxylactose PET/CT

PLoS ONE

Volumn 4, Issue 11, 2009, Pages

  Flores, Leo Garcia ^a   Bertolini, Susanna ^a   Yeh, Hsin Hsin ^a   Young, Daniel ^a   Mukhopadhyay, Uday ^a   Pal, Ashutosh ^a   Ying, Yunming ^a   Volgin, Andrei ^a   Shavrin, Aleksandr ^a   Soghomonyan, Suren ^a   Tong, William ^a   Bornmann, William ^a   Alauddin, Mian M ^a   Logsdon, Craig ^a   Gelovani, Juri G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 DEXTRO GALACTOPYRANOSYL (1,4') 2' [F 18]FLUOROETHYL DEXTRO GLUCOPYRANOSE; GALAPTIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; FLUORINE; LACTOSE; LECTIN; LIGAND; O GALACTOPYRANOSYL (1 4') 2' DEOXY 2' FLUOROETHYLGLUCOPYRANOSE; O-GALACTOPYRANOSYL-(1-4')-2'-DEOXY-2'-FLUOROETHYLGLUCOPYRANOSE; PANCREATITIS ASSOCIATED PROTEIN; PANCREATITIS-ASSOCIATED PROTEIN; TUMOR ANTIGEN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITOMETRY; DRUG CLEARANCE; DRUG HALF LIFE; IMMUNOHISTOCHEMISTRY; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; PANCREAS CARCINOMA; PROTEIN EXPRESSION; SHAM PROCEDURE; ACINAR CELL CARCINOMA; ANIMAL; BIOLOGICAL MODEL; CANCER TRANSPLANTATION; CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; METABOLISM; METHODOLOGY; PANCREAS; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

MURINAE; MUS;

ANIMALS; ANTIGENS, NEOPLASM; CARCINOMA; CARCINOMA, ACINAR CELL; FLUORINE RADIOISOTOPES; LACTOSE; LECTINS, C-TYPE; LIGANDS; MICE; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; PANCREAS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 71049134872     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007977     Document Type: Article

References (36)

1. National Cancer Institute N, U.S. http://www.cancer.gov/cancertopics/ types/pancreatic (2009) Pancreatic Cancer (Online).
2. Koorstra JB, Hustinx SR, Offerhaus GJ, Maitra A (2008) Pancreatic carcinogenesis. Pancreatology 8: 110-125.
3. Evans D (1997) Cancer of the pancreas. Philadelphia: Lippincott. pp 1054-1087.
4. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, et al. (1997) Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 226: 248-257; discussion 257-260.
5. Pakzad F, Groves AM, Ell PJ (2006) The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 36: 248-256.
6. Fukushima N, Koopmann J, Sato N, Prasad N, Carvalho R, et al. (2005) Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma. Mod Pathol 18: 779-787.
7. Rosty C, Christa L, Kuzdzal S, Baldwin WM, Zahurak ML, et al. (2002) Identification of hepatocarcinoma-intestine-pancreas/ pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 62: 1868-1875.
8. Hervieu V, Christa L, Gouysse G, Bouvier R, Chayvialle JA, et al. (2006) HIP/PAP, a member of the reg family, is expressed in glucagon-producing enteropancreatic endocrine cells and tumors. Hum Pathol 37: 1066-1075.
9. Drickamer K (1999) C-type lectin-like domains. Curr Opin Struct Biol 9: 585-590.
10. Iovanna JL, Dagorn JC (2005) The multifunctional family of secreted proteins containing a C-type lectin-like domain linked to a short N-terminal peptide. Biochim Biophys Acta 1723: 8-18.
11. Christa L, Felin M, Morali O, Simon MT, Lasserre C, et al. (1994) The human HIP gene, overexpressed in primary liver cancer encodes for a C-type carbohydrate binding protein with lactose binding activity. FEBS Lett 337: 114-118.
12. Bormans G, Verbruggen A (2001) Enzymatic synthesis and biodistribution in mice of β-O D-galactopyranosyl-(1,4′)-2′-[18F]fluoro- 2′-deoxy-D-glucopyranose (2′-[18F]fluorodeoxylactose). J Labelled Cpd Radiopharm 44: 417-423.
13. Ying Y, Ghosh P, Guo L, Pal A, Mukhopadhyay U, et al. (2009) Synthesis and ex vivo autoradiographic evaluation of ethyl-β-D-galactopyranosyl-(1,4′)-2′- deoxy-2′-[18F]fluoro-β-D-glucopyranoside - a novel radioligand for lactose-binding protein: implications for early detection of pancreatic carcinomas with PET. J Med Chem (in press).
14. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, et al. (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16: 834-840.
15. Simon MT, Pauloin A, Normand G, Lieu HT, Mouly H, et al. (2003) HIP/PAP stimulates liver regeneration after partial hepatectomy and combines mitogenic and anti-apoptotic functions through the PKA signaling pathway. Faseb J 17: 1441-1450.
16. Christa L, Simon MT, Brezault-Bonnet C, Bonte E, Carnot F, et al. (1999) Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/ PAP) is expressed and secreted by proliferating ductules as well as by hepatocarcinoma and cholangiocarcinoma cells. Am J Pathol 155: 1525-1533.
17. Hruban RH, Canto MI, Yeo CJ (2001) Prevention of pancreatic cancer and strategies for management of familial pancreatic cancer. Dig Dis 19: 76-84.
18. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK Jr, et al. (1997) Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 89: 442-446.
19. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, et al. (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119: 1447-1453.
20. Lal G, Liu G, Schmocker B, Kaurah P, Ozcelik H, et al. (2000) Inherited predisposition to pancreatic adenocarcinoma: role of family history and germline p16, BRCA1, and BRCA2 mutations. Cancer Res 60: 409-416.
21. Rulyak SJ, Lowenfels AB, Maisonneuve P, Brentnall TA (2003) Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 124: 1292-1299.
22. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB (1999) Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 131: 247-255.
23. Goggins M, Canto M, Hruban R (2000) Can we screen high-risk individuals to detect early pancreatic carcinoma? J Surg Oncol 74: 243-248.
24. Honda K, Hayashida Y, Umaki T, Okusaka T, Kosuge T, et al. (2005) Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res 65: 10613-10622.
25. Yokoi K, Shih LC, Kobayashi R, Koomen J, Hawke D, et al. (2005) Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. Int J Oncol 27: 1361-1369.
26. Yamaguchi K, Enjoji M, Nakashima M, Nakamuta M, Watanabe T, et al. (2005) Novel serum tumor marker, RCAS1, in pancreatic diseases. World J Gastroenterol 11: 5199-5202.
27. Chakrabarti A, Zhang K, Aruva MR, Cardi CA, Opitz AW, et al. (2007) Radiohybridization PET imaging of KRAS G12D mRNA expression in human pancreas cancer xenografts with [(64)Cu]DO3A-peptide nucleic acid-peptide nanoparticles. Cancer Biol Ther 6: 948-956.
28. Ohuchida K, Mizumoto K, Yamada D, Yamaguchi H, Konomi H, et al. (2006) Quantitative analysis of human telomerase reverse transcriptase in pancreatic cancer. Clin Cancer Res 12: 2066-2069.
29. Nakashima A, Murakami Y, Uemura K, Hayashidani Y, Sudo T, et al. (2009) Usefulness of human telomerase reverse transcriptase in pancreatic juice as a biomarker of pancreatic malignancy. Pancreas 38: 527-533.
30. Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, et al. (2006) New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 24: 252-258.
31. Gold DV, Goldenberg DM, Karacay H, Rossi EA, Chang CH, et al. (2008) A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res 68: 4819-4826.
32. Cerwenka H, Aigner R, Bacher H, Werkgartner G, el-Shabrawi A, et al. (2001) Pancreatitis-associated protein (PAP) in patients with pancreatic cancer. Anticancer Res 21: 1471-1474.
33. Xie MJ, Motoo Y, Iovanna JL, Su SB, Ohtsubo K, et al. (2003) Overexpression of pancreatitis-associated protein (PAP) in human pancreatic ductal adenocarcinoma. Dig Dis Sci 48: 459-464.
34. Motoo Y, Watanabe H, Yamaguchi Y, Xie MJ, Mouri H, et al. (2001) Pancreatitis-associated protein levels in pancreatic juice from patients with pancreatic diseases. Pancreatology 1: 43-47.
35. Nishii R, Volgin AY, Mawlawi O, Mukhopadhyay U, Pal A, et al. (2008) Evaluation of 2′-deoxy-2′-[18F]fluoro-5-methyl-1-beta-L: -arabinofuranosyluracil ([18F]-L-FMAU) as a PET imaging agent for cellular proliferation: comparison with [18F]-D-FMAU and [18F]FLT. Eur J Nucl Med Mol Imaging 35: 990-998.
36. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ (1999) In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1: 50-62.